ARA-290 (Cibinetide)

Cardiovascular Health · ['Cibinetide', 'ARA290', 'pHBSP', 'erythropoietin-derived peptide']

An 11-amino-acid peptide derived from the tertiary structure of erythropoietin, designed to selectively engage the innate repair receptor without stimulating erythropoiesis; studied in tissue-protection and neuropathic-pain research.

🔬 Research use only — not for human or veterinary use. K4 Elite does not provide dosing instructions.

Molecular Formula

C51H84N16O21

Molecular Weight

1257.3 g/mol

PubChem

CID 91810664 ↗

Research Level

Emerging Research

Browse the store →

ARA-290, also known as cibinetide, is a short synthetic peptide of eleven amino acids whose sequence corresponds to a specific region on the surface of the erythropoietin (EPO) molecule. Researchers designed it to reproduce the tissue-protective signaling attributed to EPO while avoiding EPO's effect on red-blood-cell production.

Native EPO signals through two receptor systems: the classical homodimeric EPO receptor that drives erythropoiesis, and a distinct tissue-protective complex sometimes termed the innate repair receptor (a heteromer of the EPO receptor and the beta-common receptor, CD131). ARA-290 was engineered to engage the latter selectively.

The peptide has a verified PubChem record (CID 91810664) and is studied in models of inflammation, neuropathic pain, and tissue injury. It is supplied strictly as a research reagent.

ARA-290 is proposed to bind the innate repair receptor, a heterocomplex of the EPO receptor and the beta-common receptor (CD131). Activation of this receptor in experimental models is associated with anti-inflammatory and cytoprotective signaling, including modulation of pathways that reduce apoptosis and inflammatory cytokine activity in injured tissue.

Because ARA-290 does not activate the homodimeric EPO receptor responsible for erythropoiesis, laboratory studies report that it does not raise red-cell mass, distinguishing its signaling profile from full-length EPO.

Innate repair receptor / beta-common receptor signaling and tissue protection
Neuropathic pain and small-fiber neuropathy in clinical and preclinical models
Anti-inflammatory signaling in models of metabolic and autoimmune disease
Cardiac and vascular ischemia-reperfusion injury research
Sarcoidosis-associated neuropathy investigation

📋 How published studies were conducted — a research reference summarizing study designs from the literature. This is not usage, dosing, or administration guidance. K4 Elite does not provide dosing instructions; determining any research protocol is the sole responsibility of the qualified researcher.

These summarize published research for informational purposes only and are not usage directions.

Clinical research has evaluated cibinetide in small-fiber neuropathy; Dahan and colleagues and later trials in patients with sarcoidosis-associated neuropathy reported changes in corneal nerve-fiber and pain measures in controlled study settings (cibinetide/ARA-290 neuropathy trials).

Preclinical work by Brines and Cerami established the concept of tissue-protective EPO derivatives, demonstrating in animal models that ARA-290 signaling reduced markers of tissue injury without stimulating erythropoiesis.

Combinations examined in the research literature. Descriptive only — not a recommendation to combine compounds.

Erythropoietin (EPO)Compatible

ARA-290 is derived from EPO's tissue-protective domain but selectively avoids the erythropoietic receptor; studied as a comparator.

Beta-common receptor (CD131)Synergistic

A component of the innate repair receptor ARA-290 is proposed to engage in tissue-protection research.

Pro-inflammatory cytokines (e.g., TNF-alpha)Neutral

Studied as downstream readouts of ARA-290's proposed anti-inflammatory signaling.

VIP (Vasoactive Intestinal Peptide)Compatible

Another peptide with anti-inflammatory and vascular research interest; sometimes examined in parallel.

References are being compiled for this entry.

What is ARA-290?

ARA-290 (cibinetide) is an 11-amino-acid peptide derived from a surface region of erythropoietin, designed to activate tissue-protective signaling without stimulating red-blood-cell production.

What is its PubChem CID?

ARA-290 is PubChem CID 91810664, with molecular formula C51H84N16O21 and a molecular weight near 1257.3.

How does it differ from EPO?

In laboratory models it engages the innate repair receptor for cytoprotective signaling but does not activate the classical EPO receptor that drives erythropoiesis, so it does not raise red-cell mass.

What research areas involve ARA-290?

Studies span innate-repair-receptor signaling, neuropathic pain and small-fiber neuropathy, anti-inflammatory effects, and ischemia-reperfusion injury models.

Is ARA-290 for human or veterinary use?

No. It is provided for laboratory research use only and is not intended to diagnose, treat, cure, or prevent any disease in humans or animals.

Disclaimer: This profile summarizes published preclinical and laboratory research for reference only. It is not medical advice and makes no claim of safety or efficacy in humans. Determining any research protocol is the sole responsibility of the qualified researcher. Products are sold strictly for in-vitro research and have not been evaluated by the FDA.